Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms): Part II - Specific NE tumour types

Acta Oncologica

Volumn 43, Issue 7, 2004, Pages 626-636

  Öberg, Kjell ^a   Astrup, Lone ^b   Eriksson, Barbro ^a   Falkmer, Sture E ^c   Falkmer, Ursula G ^c   Gustafsen, Jens ^d   Haglund, Caj ^e   Knigge, Ulrich ^d   Vatn, Morten H ^f   Välimäki, Matti ^e  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DIAZOXIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLUCAGON; INTERFERON; KETOCONAZOLE; METYRAPONE; PROTON PUMP INHIBITOR; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN;

APPENDIX CANCER; ATROPHIC GASTRITIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL PRACTICE; COLON CARCINOMA; CUSHING DISEASE; DUODENUM CARCINOMA; GASTRINOMA; GASTROINTESTINAL TUMOR; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; HYPOGLYCEMIA; ILEUM CANCER; LUNG CARCINOMA; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECTUM CARCINOMA; REVIEW; STOMACH CARCINOMA; THYMUS CANCER; TUMOR DIFFERENTIATION;

GASTROINTESTINAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; THYMUS NEOPLASMS;

EID: 9444236228     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860410018584     Document Type: Review

References (56)

1. Modlin IM. Lye KD, Kidd M. A 5-decade analysis of 13.715 carcinoid tumors. Cancer 2003; 97: 934-9.
2. Rindi G. Azzoni C, La Rosa S. et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999; 116: 532-42.
3. Soga J. Gastric carcinoids: a statistical evaluation of 1.094 cases collected from the literature. Surg Today 1997; 27: 892-901.
4. Granberg D, Wilander E. Stridsberg M. Graneurs G. Skogseid B, Oberg K. Clinical symptoms, hormone profiles, treatment and prognosis in patients with gastric carcinoids. Gut 1998; 43: 223-8.
5. Akerstrom G. Management of carcinoid tumors of the stomach, duodenum and pancreas. World J Surg 1996; 20: 173-82.
6. Stamm B, Hedinger CE, Saremaslani P. Duodenal and ampullary carcinoid tumors: report of 12 cases with pathological characteristics, polypeptide content and relation to MEN-I syndrome and von Recklinghausen's disease (neurofibromatosis). Virchow Arch A 1986; 408: 475-89.
7. Burke AP, Federspiel BH, Sobin LH, Shekitka KM, Helwig EB. Carcinoids of the duodenum: a histologic and immunohistochemical study of 65 tumors. Am J Surg Pathol 1989; 13(10): 828-37.
8. Solcia E, Sessa F, Rindi R, Bonato M, Capella C. Pancreatic endocrine tumors: General concepts; non-functioning tumors and tumors with uncommon function. In: Dayal Y. ed. Endocrine pathology of the gut and pancreas. Boca Raton: CRC Press: 1999. p. 105-31.
9. Skogseid B. Oberg K, Eriksson B. Juhlin C, Granberg D. Akterstrom G, Rastad J. Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type 1. World J Surg 1996; 20: 827-77.
10. Grand CS. Gastrointestinal endocrine tumors. Insulinoma. Baillieres Clin Gastroenterol 1996; 10: 645-71.
11. Falkmer S. Origin of the parenchymal cells of the endocrine pancreas: some phylogenetic and ontogenetic aspects. Front Gastrointest Res 1995; 23: 2-29.
12. Klöppel G. Höfler H, Heitz PU. Pancreatic endocrine tumours in man. In: Polak JM. ed. Diagnostic histopathology of neuroendocrine tumours. Edinburgh: Churchill Livingstone; 1993. p. 91-121.
13. Evans DB, Skibber JM, Lee JE. Non-functioning islet cell carcinomas of the pancreas. Surgery 1993; 114: 1175-82.
14. Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 2001; 321: 306-20.
15. Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 1998; 17: 389-400.
16. Roy PK, Venzon DJ, Shojamenesh H, et al. Zolinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 2000; 79: 379-411.
17. Soga J, Yakuva Y Somatostatinoma/inhibitory syndrome; a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 1999; 18: 13-22.
18. Skogseid B, Oberg K, Benson L, et al. A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in Multiple Endocrine Neoplasia Type 1 syndrome: Five years experience. J Clin Endocrinol Metab 1987; 64: 1233-40.
19. Frucht H, Howard JM, Slaff JJ, et al. Secretin and calcium provocative tests in the Zolinger-Ellison syndrome; a prospective study. Ann Intern Med 1989; 111: 713-22.
20. Doppman JL, Chang R, Fraker DL, et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med 1995; 123: 269-73.
21. Ricke J, Klose K-J. Mignon M, Oberg K, Wiedenmann B. Standardization of imaging in neuroendocrine tumors: results of a European Delphi process. Eur J Radiol 2001; 37: 8-17.
22. Kwekkeboom D, Krenning EP, De Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41: 1704-13.
23. Orlefors H, Sundin A, Ahlstrom H, et al. Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumors. J Clin Oncol 1998; 16: 2534-41.
24. Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopie ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000; 95: 2271-7.
25. Wolfe MM. Jensen RT Zolinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med 1987; 317: 1200-9.
26. Wiedenmann B, Jensen RT, Mignon M. et al. Preoperative diagnosis and surgical management of neuroendocrine pancreatic tumors: general recommendations by a consensus workshop. World J Surg 1998; 22: 309-18.
27. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001; 12(Suppl 2): 111-4.
28. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000; 62(Suppl 1): 73-8.
29. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-32.
30. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-23.
31. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994; 120: 302-9.
32. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 2000; 62(Suppl 1): 92-7.
33. Fjallskog ML, Sundin A. Westlin JE, Oberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of α-interferon and somatostatin analogs. Med Oncol 2002; 19: 35-42.
34. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and α-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999; 94: 1381-8
35. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999; 10(Suppl 2): 31-8.
36. Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998; 93: 1468-71.
37. Aparcio T, Ducreux M, Baudin E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001; 37: 1014-9.
38. Wymenga AN, Eriksson B. Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone related symptoms. J Clin Oncol 1999; 17: 1111-7.
39. Berge T, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand [A] 1976; 84: 322-30.
40. Soga J, Yakuva Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res 1999; 18: 133-41.
41. Wilander E, Scheibenflug L. Eriksson B, Öberg K. Diagnostic criteria of classical carcinoids. Acta Oncol 1991; 30: 469-75.
42. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumours. Lancet 1998; 352: 799-805.
43. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340: 858-68.
44. Soga J. Carcinoids of the colon and ileocecal region: a statistical evaluation of 363 cases collected from the literature. J Exp Clin Cancer Res 1998; 17: 139-48.
45. Moertel CG, Weiland LH, Nagorney DM, Docherty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987; 317: 1699-701.
46. Kanthan R, Saxena A, Kanthan SC. Goblet cell carcinoids of the appendix: immunophenotype and ultrastructural study. Arch Pathol Lab Med 2001; 125: 386-90.
47. Federspiel BH, Burke AP, Sobin LH, Shetitka KM. Rectal and colonic carcinoids. A clinicopathologic study of 84 cases. Cancer 1990; 65: 135-40.
48. Rosenberg JM, Welsh JP. Carcinoid tumors of the colon: a study of 72 patients. Am J Surg 1985; 149: 775-9.
49. Shimizu T, Tanaka S, Haruma K, et al. Growth characteristics of rectal Carcinoid tumors. Oncology 2000; 59: 229-37.
50. Kura AN, Giacco GG, Curley SA. Skibber JM, Feig BW, Ellis LM. Carcinoid tumors of the rectum. Effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer 1997; 79: 1294-8.
51. Soga J, Yakura Y, Osaka M. Evaluation of 243 cases of mediastinal/thymic carcinoids collected from the literature: a comparative study between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg 1999; 5: 285-92.
52. Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathological analysis of 80 cases. Am J Clin Pathol 2000; 114: 100-10.
53. Fink G, Krelbaum T, Yellin A. et al. Pulmonary carcinoid: presentation, diagnosis and outcome in 142 cases in Israel and review of 6440 cases from the literature. Chest 2001; 119: 1647-51.
54. Laitinen KLJ, Soini Y, Matilla J, Paakko P. Atypical bronchopulmonary carcinoids show a tendency towards increased apoptotic and proliferative activity. Cancer 2000; 88: 1590-8.
55. Zhao J, de Krijger RR, Meier D. et al. Genomic alterations in well-differentiated gastrointestianl and bronchial neuroendocrine tumors (carcinoids). Am J Pathol 2000; 157: 1431-8.
56. Granberg D, Wilander E, Oberg K, Skogseid B. Prognostic markers in patients with typical bronchial carcinoid tumors. J Clin Endocrinol Metab 2000; 85: 3425-30.